Match!
Yoon Jun Kim
Seoul National University
VirologyHepatitis BHepatocellular carcinomaHepatitis B virusMedicine
381Publications
39H-index
6,234Citations
What is this?
Publications 404
Newest
#1Jeong-Hoon Lee (SNU: Seoul National University)H-Index: 24
#2Yun Bin Lee (SNU: Seoul National University)H-Index: 12
Last. Yoon Jun Kim (SNU: Seoul National University)H-Index: 39
view all 6 authors...
BACKGROUND HBsAg seroclearance is considered a functional cure for patients with chronic hepatitis B, but is rarely achievable with oral nucleos(t)ide analogs alone. We conducted a randomized controlled proof-of-concept trial to evaluate the impact of adding pegylated interferon (Peg-IFN) alfa-2a plus sequential or concomitant hepatitis B virus (HBV) vaccination. METHODS A total of 111 patients who achieved serum HBV DNA <20 IU/mL and quantitated HBsAg (qHBsAg) <3,000 IU/mL with entecavir were r...
Source
#1Joon Yeul Nam (Ewha Womans University)H-Index: 5
#2A. Reum Choe (Ewha Womans University)
Last. Jin Wook Chung (SNU: Seoul National University)H-Index: 54
view all 16 authors...
The decision of transarterial chemoembolization (TACE) initiation and/or repetition remains challenging in patients with unresectable hepatocellular carcinoma (HCC). The aim was to develop a prognostic scoring system to guide TACE initiation/repetition. A total of 597 consecutive patients who underwent TACE as their initial treatment for unresectable HCC were included. We derived a prediction model using independent risk factors for overall survival (OS), which was externally validated in an ind...
Source
#1Cheol-Hyung Lee (SNU: Seoul National University)
#2Yun Bin Lee (SNU: Seoul National University)H-Index: 12
Last. Su Jong Yu (SNU: Seoul National University)H-Index: 22
view all 13 authors...
Background/Aims Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients. Methods Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inve...
Source
#1Philippe MerleH-Index: 32
#2Do Hoon Lim (SMC: Samsung Medical Center)H-Index: 42
Last. Masayuki KurosakiH-Index: 36
view all 16 authors...
Source
#1Sang Hoon Ahn (Yonsei University)H-Index: 49
#2Won Hyeok Choe (Konkuk University)H-Index: 17
Last. Seung Woon Paik (SMC: Samsung Medical Center)H-Index: 40
view all 7 authors...
Background/Aims: Chronic hepatitis C virus (HCV) infections put patients at risk of serious liver disease and adversely affects patient quality of life (QoL). MOSAIC (International Multicenter Prospective Observational Study to Evaluate the Epidemiology, Humanistic and Economic Outcomes of Treatment for Chronic Hepatitis C Virus) was a prospective, non-interventional, international, multicenter study that aimed to describe the epidemiology of the infection, the impact of the infection on health-...
Source
#1Yoo Je (SCH: Soonchunhyang University)H-Index: 1
#1Jeong Ju Yoo (SCH: Soonchunhyang University)H-Index: 12
Last. Jung-Hwan Yoon (SNU: Seoul National University)H-Index: 46
view all 9 authors...
Background/Aims: Patients with an intermediate stage of hepatocellular carcinoma (HCC) represent a highly heterogeneous population; therefore, many models have been proposed to predict the survival of these patients. The aim of this study was to evaluate the prognostic performance of a novel subclassification for tumors classified as Barcelona Clinic Liver Cancer (BCLC) stage B using the Model to Estimate Survival in Ambulatory HCC patients (MESIAH). Methods: This analysis was based on 377 patie...
1 CitationsSource
#1Hyung Joon Yim (KU: Korea University)H-Index: 23
#2Won Kim (Seoul Metropolitan Government)H-Index: 26
Last. Dong Joon Kim (Hallym University)H-Index: 24
view all 24 authors...
OBJECTIVES: Chronic hepatitis B (CHB) remains a major worldwide public health concern. Besifovir dipivoxil maleate (BSV) is a new promising treatment for CHB. However, long-term efficacy and safety have not yet been evaluated. Therefore, the goal of the study is to determine the antiviral efficacy and safety of BSV treatment over a 144-week duration (BSV-BSV) in comparison with those of a sequential treatment with tenofovir disoproxil fumarate (TDF) followed by a 96-week duration BSV administrat...
Source
#1Hyue Mee Kim (CAU: Chung-Ang University)
#1Hyue Mee Kim (Seoul National University Hospital)H-Index: 3
Last. Jung-Hwan Yoon (SNU: Seoul National University)H-Index: 46
view all 11 authors...
BACKGROUND: Cardiac dysfunction is increasingly recognized in patients with liver cirrhosis. Nevertheless, the presence or absence of structural alterations such as diffuse myocardial fibrosis remains unclear. We aimed to investigate myocardial structural changes in cirrhosis, and explore left ventricular (LV) structural and functional changes induced by liver transplantation. METHODS: This study included 33 cirrhosis patients listed for transplantation and 20 healthy controls. Patients underwen...
Source
#1Gyu Chul OhH-Index: 1
#1Gyu Chul Oh (Seoul National University Hospital)H-Index: 3
Last. Hae-Young Lee (Seoul National University Hospital)H-Index: 32
view all 6 authors...
Purpose: Fimasartan, the ninth and most recent angiotensin receptor blocker (ARB) approved by the Korea Food and Drug Administration, has shown similar efficacy and safety profiles compared to other ARBs. However, due to being predominantly excreted by the hepatobiliary system, concerns on safety have been raised regarding its use in patients with underlying liver disease. Patients and Methods: This prospective, 12-month, observational study evaluated patients with essential hypertension (HTN) r...
Source
#1Young Youn Cho (CAU: Chung-Ang University)H-Index: 11
#2Su Jong YuH-Index: 22
Last. Jung-Hwan YoonH-Index: 46
view all 11 authors...
Background/Aims:Transarterial chemoembolization (TACE) is a major therapeutic modality for patients with unresectable hepatocellular carcinoma, which needs repeated treatments. Model to Estimate Survival in Ambulatory Hepatocellular carcinoma patients (MESIAH) was recently developed as a model for p
Source
12345678910